ALDH1A1 expression in benign and malignant prostate tissues
Keywords:
Prostate cancer, ALDH1A1, ImmunohistochemistryAbstract
Summary Background: Prostate cancer has few prognostic biomarkers, and differentiating between relapsing and non-relapsing tumour can be challenging clinically. Aims: This study aims to investigate the hypothesis that ALDH1A1 might be a potential biomarker for prostate tumors and could distinguish between aggressive tumours requiring radical intervention and those that have a good prognosis. It is thought to be a potential biomarker that can predict the clinical progression and prognosis of different kinds of tumours. However, its role in prostate cancer remains unclear. Materials and methods: ALDH1A1 expression has been evaluated by immunohistochemistry using 96 prostate tissue samples including normal, adjacent normal and cancer tissues. Results: This study showed that ALDH1A1 was expressed in glandular and stromal regions of both benign and malignant prostate tissues. Nuclear and cytoplasmic ALDH1A1 was increased significantly in glandular regions of prostate cancer and was positively associated with increased tumor size. However, stromal ALDH1A1 staining was not associated with prostate cancer and other parameters such as primary Gleason grade and stage. Conclusion: This preliminary data suggests that ALDH1A1 may have a role in cancer development and/or aggressiveness and warrants further investigation to understand its function and establish if it could be a potential diagnostic biomarker for prostate cancer.References
Lang, S.H.; Frame, F.M. & Collins, A.T. Prostate cancer stem cells. The Journal of pathology, , 2009, 217(2), pp. 299-306.
Kirby, R.S. Prostate cancer. 7th ed.; Abingdon: Abingdon: Health Press, 2012.
Bagnall, P. Diagnosis and treatment of prostate cancer. Nursing times, 2014, 110(9), p. 12.
Dunn, M.W. & Kazer, M.W. Prostate Cancer Overview. Seminars in Oncology Nursing, 2011, 27(4), pp. 241-250.
Qu, M.; Ren, S.C. & Sun, Y.H. Current early diagnostic biomarkers of prostate cancer. Asian journal of andrology, 2014, 16(4), pp. 549-54.
Kahlert, C., Gaitzsch, E., Steinert, G., Mogler, C., Herpel, E., Hoffmeister, M., Jansen, L., Benner, A., Brenner, H., Chang-Claude, J., Rahbari, N., Schmidt, T., Klupp, F., Grabe, N., Lahrmann, B., Koch, M., Halama, N., Buchler, M. & Weitz, J. Expression analysis of aldehyde dehydrogenase 1A1 (ALDH1A1) in colon and rectal cancer in association with prognosis and response to chemotherapy. Annals of surgical oncology, 2012.19(13), pp. 4193-201.
Li, X.S., Xu, Q., Fu, X.Y. & Luo, W.S . ALDH1A1 overexpression is associated with the progression and prognosis in gastric cancer. BMC Cancer, 2014. 14(1).
Tomita H, Tanaka K, Tanaka T, Hara A. Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget. 2016 8;7(10):11018-32. doi: 10.18632/oncotarget.6920. PMID: 26783961; PMCID: PMC4905455.
Yoshida, G.J.Emerging roles of Myc in stem cell biology and novel tumor therapies. Journal of experimental & clinical cancer research : 2018, CR, 37(1), pp. 173-173.
Matsika, A., Srinivasan, B., Day, C., Mader, S.A., Kiernan, D.M., Broomfield, A., Fu, J., Hooper, J.D., Kench, J.G. & Samaratunga, H.,. Cancer stem cell markers in prostate cancer: an immunohistochemical study of ALDH1, SOX2 and EZH2. Pathology, 2015, 47(7), p. 622.
Deng, S., Yang, X., Lassus, H., Liang, S., Kaur, S., Ye, Q., Li, C., Wang, L.-P., Roby, K.F., Orsulic, S., Connolly, D.C., Zhang, Y., Montone, K., Bützow, R., Coukos, G. & Zhang, L.,. Distinct Expression Levels and Patterns of Stem Cell Marker, Aldehyde Dehydrogenase Isoform 1 ( ALDH1), in Human Epithelial Cancers ( ALDH1 in Epithelial Cancers). PLoS ONE, 2010, 5(4), p. e10277.
Ting, L., Yun, S., Yuping, M., Qixin, L., Bingjie, L., Zhenqiu, L., Sanford, A.S. & Feng, J. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients’ outcome. Laboratory Investigation, 2009. 90(2), p. 234.
